These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28848182)

  • 1. Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
    Aarts MJ; Vriens BE; de Boer M; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Tol J; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; van der Rijt CCD; Smilde TJ; van der Velden AW; Peer N; Tjan-Heijnen VCG
    Oncology; 2017; 93(5):323-328. PubMed ID: 28848182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
    Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
    Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.
    Sveikata A; Liutkauskienė S; Juozaitytė E; Characiejus D; Tamošaitytė L; Šeštakauskas K
    Medicina (Kaunas); 2011; 47(8):428-33. PubMed ID: 22123557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
    Meza LA; Green MD; Hackett JR; Neumann TA; Holmes FA
    Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
    J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
    Fleming DR; Goldsmith J; Goldsmith GH; Stevens DA; Herzig RH
    J Hematother Stem Cell Res; 2000 Dec; 9(6):855-60. PubMed ID: 11177597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
    Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK; Feng FY; Sun Y
    Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.